- Home
- PLCE vs BDTX Comparison
PLCE vs BDTX Comparison
Compare PLCE & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLCE | BDTX |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.2M | 116.8M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLCE | BDTX |
|---|---|---|
| Price | $3.57 | $2.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.50 | ★ $9.25 |
| AVG Volume (30 Days) | 230.1K | ★ 598.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.35 | 32.45 |
| EPS | N/A | ★ 0.65 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.34 | N/A |
| P/E Ratio | ★ N/A | $3.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.57 | $1.20 |
| 52 Week High | $9.56 | $4.94 |
Technical Indicators
Market Signals| Indicator | PLCE | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 43.83 |
| Support Level | N/A | $1.93 |
| Resistance Level | $4.79 | $2.67 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 7.56 | 35.21 |
Price Performance
Historical ComparisonAbout PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.